24-month AVeNEW data show significantly better target lesion patency of Covera stent compared to PTA

334

Bart Dolmatch (Portola Valley, USA) talks to Vascular News about some of the key data highlights from the 24-month AVeNEW trial, which compared the safety and efficacy of the Covera™ Vascular covered stent (BD) against percutaneous transluminal angioplasty (PTA) for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous access circuit.

The data, which was presented at CIRSE 2020, is “very compelling”, says Dolmatch, who notes that that the primary endpoints of safety at one-month and durability at six-months were “superior” for the covered stent compared to angioplasty alone. These results “hold up” at 24-months, he adds, with a greater target lesion primary patency for the covered stent compared to angioplasty (41.8% vs. 10.4%) – highlighting a “dramatic improvement” at the target lesion site.

He also discusses the importance of circuit patency when treating haemodialysis patients, stating that there is now “robust data” to show that the use of a covered stent is a “great strategy” for cephalic vein arch stenosis. Further sub-analyses show that the covered stent performed better with de novo, recurrent lesions and any other type of arteriovenous fistula, concludes Dolmatch.

This video is sponsored by BD.


LEAVE A REPLY

Please enter your comment!
Please enter your name here